AUDIOCURE-PHARMA-GMBH
22.5.2017 13:14:11 CEST | Business Wire | Press release
AudioCure, a German pharmaceutical company focusing on the development of treatments for hearing disorders, announced today that it has appointed Dr. Reimar Schlingensiepen as CEO.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170522005541/en/
Dr. Schlingensiepen has been with AudioCure as COO since July 2015. During that time, he has successfully reshaped the company and carved out the recent series A financing round of about 9 million euros. He takes over from Prof. Hans Rommelspacher, who will continue as CSO. “With Reimar´s deep commitment to AudioCure, his proven track record and over 20 years of experience in the biopharmaceutical industry spanning preclinical, clinical and product development, I could not have wished for a better person for the job of CEO,” said Prof. Rommelspacher.
Since 2008, Dr. Schlingensiepen has worked as entrepreneur and manager in the fields of biopharmaceutical development, med-tech and diagnostics. He co-founded a number of high-tech companies, where he held several management positions. In addition to his leadership and biopharmaceutical expertise, he brings to AudioCure substantial experience in manufacturing, marketing and finance. It is of great advantage to AudioCure that, as a medical doctor, Dr. Schlingensiepen also conducted a variety of clinical trials in oncology, immunology and neurology.
With AudioCure, Dr. Schlingensiepen´s immediate goal is to steer the company’s first in class front-runner molecule AC102 through its formal preclinical development. This is a prerequisite for the clinical development, which is planned in patients with auditory disorders including acute hearing loss and acute tinnitus.
“With the proof of principle for AC102 accomplished under the leadership of Prof. Rommelspacher, this is an exciting time in AudioCure’s development. We hold a gem in our hands with enormous potential for patients suffering from auditory disorders,” said Dr. Schlingensiepen. “In sharing responsibilities, Hans and I can continue on our seamless path to the clinic. I am very much looking forward to leading an AudioCure team that recognizes the unique opportunity we have to help transform the treatment landscape for hearing impairments.”
For further information: www.audiocure.de .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005541/en/
Contact:
AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 39714
E-Mail:
pr@audiocure.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible CapitalSolutions16.6.2026 01:01:00 CEST | Press release
Founded by former Blackstone executive Vlado Spasov, Trimontium is an institutionally backed alternative asset manager purpose-built to deliver flexible capital solutions across Europe and North America Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to ava
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom